MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
25.26
+0.62
+2.52%
Opening 11:41 10/03 EDT
OPEN
25.12
PREV CLOSE
24.64
HIGH
25.95
LOW
24.74
VOLUME
108.85K
TURNOVER
1.90M
52 WEEK HIGH
31.65
52 WEEK LOW
20.80
MARKET CAP
1.62B
P/E (TTM)
-6.8649
1D
5D
1M
3M
1Y
5Y
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of ind...
GlobeNewswire · 09/14 21:00
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company’s ongoing longitudinal na...
GlobeNewswire · 08/25 20:30
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/22 23:10
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
Benzinga · 08/22 13:58
Travere, CSL kidney disease drug sparsentan gets review in EU
The European Medicines Agency accepted to...
Seekingalpha · 08/22 11:30
BRIEF-CSL Vifor And Travere Therapeutics Announce EMA To Review Conditional Marketing Authorization Application For Sparsentan For Treatment Of Iga Nephropathy
BRIEF-CSL Vifor And Travere Therapeutics Announce EMA To Review Conditional Marketing Authorization Application For Sparsentan For Treatment Of Iga Nephropathy
Reuters · 08/22 11:05
Travere Therapeutics Return On Capital Employed Overview
 
Benzinga · 08/15 14:23
Piper Sandler Adjusts Price Target on Travere Therapeutics to $39 From $41, Reiterates Overweight Rating
Piper Sandler Adjusts Price Target on Travere Therapeutics to $39 From $41, Reiterates Overweight Rating
MT Newswires · 08/15 09:52
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. It is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.

Webull offers kinds of Travere Therapeutics Inc stock information, including NASDAQ:TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.